Systematic Review with Meta-Analysis

‘Catalytic’ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials

John L. Sievenpiper1,2*, Laura Chiavaroli2, Russell J. de Souza2,3,4, Arash Mirrahimi2,5, Adrian I. Cozma2,5, Vanessa Ha2,5, David Wang2,5, Matthew E. Yu2,5, Amanda J. Carleton2,5,6, Joseph Beyene3,7,8, Marco Di Buono9, Alexandra L. Jenkins2, Lawrence A. Leiter2,5,10,11, Thomas M. S. Wolever2,5,10,11, Cyril W. C. Kendall2,5,12 and David J. A. Jenkins2,5,10,11

1Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
2Clinical Nutrition and Risk Factor Modification Centre, Saint Michael’s Hospital, #6130-61 Queen Street East, Toronto, ON, Canada M5C 2T2
3Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
4Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
5Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
6Undergraduate Medical Education (MD Program), Faculty of Medicine, University of Toronto, Toronto, ON, Canada
7Faculty of Medicine, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
8Population Health Sciences Research Institute, Hospital for Sick Children, Toronto, ON, Canada
9Heart and Stroke Foundation of Ontario, Toronto, ON, Canada
10Division of Endocrinology, Saint Michael’s Hospital, Toronto, ON, Canada
11Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
12College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada

(Submitted 8 June 2011 – Final revision received 24 October 2011 – Accepted 6 January 2012 – First published online 21 February 2012)

Abstract

Contrary to concerns that fructose may have adverse metabolic effects, there is evidence that small, ‘catalytic’ doses (≤10 g/meal) of fructose decrease the glycaemic response to high-glycaemic index meals in human subjects. To assess the longer-term effects of ‘catalytic’ doses of fructose, we undertook a meta-analysis of controlled feeding trials. We searched MEDLINE, EMBASE, CINAHL and the Cochrane Library. Analyses included all controlled feeding trials ≥7 d featuring ‘catalytic’ fructose doses (≤36 g/d) in isoenergetic exchange for other carbohydrates. Data were pooled by the generic inverse variance method using random-effects models and expressed as mean differences (MD) with 95% CI. Heterogeneity was assessed by the $Q$ statistic and quantified by $I^2$. The Heyland Methodological Quality Score assessed study quality. A total of six feeding trials (n 118) met the eligibility criteria. ‘Catalytic’ doses of fructose significantly reduced HbA1c (MD $-0.40$, 95% CI $-0.72$, $-0.08$) and fasting glucose (MD $-0.25$, 95% CI $-0.44$, $-0.07$). This benefit was seen in the absence of adverse effects on fasting insulin, body weight, TAG or uric acid. Subgroup and sensitivity analyses showed evidence of effect modification under certain conditions. The small number of trials and their relatively short duration limit the strength of the conclusions. In conclusion, this small meta-analysis shows that ‘catalytic’ fructose doses (≤36 g/d) may improve glycaemic control without adverse effects on body weight, TAG, insulin and uric acid. There is a need for larger, longer (≥6 months) trials using ‘catalytic’ fructose to confirm these results.

Key words: Fructose; Sugars; ‘Catalytic’; Cardiometabolic risk; Glycaemic control; Body weight; TAG

Abbreviations: GI, glycaemic index; MD, mean differences; MQS, Methodological Quality Score.

* Corresponding author: Dr J. L. Sievenpiper, fax +1 416 867 7495, email john.sievenpiper@utoronto.ca
Table 1. Characteristics of controlled feeding trials investigating the effect of catalytic doses (≤36 g/d) of fructose on cardiometabolic endpoints

(Mean values and standard deviations)

| Study | Subjects | Age (years) | Setting | Design | Feeding control* | Randomisation | Fructose dose (g/d)† | Fructose forms‡ | Fructose delta Comparator§ | Diet † | Energy balance | Follow-up (weeks) | MQS† | Funding type** |
|-------|----------|-------------|---------|--------|-----------------|---------------|---------------------|-----------------|----------------------|--------|----------------|-----------------|--------|----------------|
| Rizkalla et al. (1986) (Expt 1) | 23 OW/OB | 22.2 | OP, France | P | Met | Yes | 36 | Liquid | Absolute Glucose Galactose | 25:50:25 | Negative | 2 | 8 | Agency–industry |
| Rizkalla et al. (1986) (Expt 2) | 18 OW/OB | 22.2 | OP, France | P | Met | Yes | 36 | Liquid | Absolute Glucose Galactose | 25:50:25 | Negative | 2 | 8 | Agency–industry |
| Grigorescu et al. (1988) | 8 DM2 (5M:3F) | 40 | 20 | OP, France | C | S | Yes | 30 | Liquid | Net Starch | 50:30:20 | Neutral | 8 | 8 | Agency–industry |
| Blayo et al. (1990) | 14 DM1, 6 DM2 | 46.9 | 13.1 | OP, France | P | S | Yes | ~25 | Mixed | Net Starch | Sucrose | 55:30:15 | Neutral | 52 | 7 | Agency–industry |
| Sunehag et al. (2002) | 24 N adolescents (12M:12F) | 10.7 | 10.7 | IP/OP, USA | P | Met | Yes | ~35.5 | Mixed | Net Starch | Sucrose | 60:25:15 | Neutral | 1 | 10 | Agency |
| Vaisman et al. (2006) | 25 DM2 | 65.4 | 10.7 | OP, Israel | P | S | Yes | 22.5 | – | Net Starch | – | Neutral | 12 | 6 | – |

MQS, Methodological Quality Score; OW/OB, overweight/obese; OP, outpatient; P, parallel; Met, metabolic; DM2, type 2 diabetes mellitus; M, male; F, female; C, cross-over; S, supplement; DM1, type 1 diabetes mellitus; N, normal; IP, inpatient.

* Met feeding control represents the provision of all meals, snacks and study supplements (test sugars and foods) during the study. S feeding control represents the provision of study supplements.

† Doses preceded by ‘ ’ represent average doses, where fructose was administered on % energy or g/kg body-weight basis.

‡ Fructose was provided in one of two forms: (1) a liquid form, where all or most of the fructose was provided as beverages or crystalline fructose to be added to beverages, or (2) in a mixed form, where all or most of the fructose was provided as beverages, solid foods and/or crystalline fructose to be added to beverages and/or foods.

§ Comparator refers to the reference carbohydrate (starch, sucrose or glucose).

† The Heyland MQS assigns scores from 0 to 1 or 0 to 2 over nine categories of quality related to study design, sampling procedures and interventions for a total of thirteen points. Trials scored ≥8 were considered high quality[10].

** Agency funding represents funding from government, university or not-for-profit health agency sources. None of the trialists declared any conflicts of interest.
There is a consensus among diabetes and heart associations in the recommendation to restrict the intake of fructose to avoid adverse metabolic effects\(^{(1,2)}\). Whether there is a level of fructose such as that provided by fruit below which there may be benefit is unclear. An emerging literature has shown that low-dose fructose (≤10 g/meal) may benefit glycaemic control. Fructose, through its metabolite fructose-1-P, has been shown to have catalytic effects on hepatic glucose metabolism by increasing glucokinase activity\(^{(3)}\). This mechanism has been shown to relate to an approximately 30% decrease in hepatic glucose production under hyperglycaemic conditions in type 2 diabetic subjects\(^{(3)}\) and an approximately 3-fold increase in glycogen synthesis by \(^{13}\)C NMR spectroscopy under euglycaemic conditions in non-diabetic subjects\(^{(4)}\). Translation of these findings in the acute clinical setting has shown that ‘catalytic’ fructose doses (≤10 g/meal) can decrease the postprandial glycaemic response to high-glycaemic index (GI) meals from about 15 to 30%\(^{(5–7)}\). To assess whether this benefit is sustainable without adverse effects on other aspects of metabolic control, we undertook a meta-analysis of controlled feeding trials of ‘catalytic’ fructose doses.

### Study Details

| Study or subgroup          | Year | n  | Wt (%) | MD, IV, random effects | 95% CI | Heterogeneity: \(\chi^2 = 0.04; \chi^2 = 5.80, df = 4 (P = 0.21); I^2 = 31\%\) |
|---------------------------|------|----|--------|------------------------|--------|-----------------------------------------------------------------------------------|
| Rizkalla et al. (Expt 1)\(^{(14)}\) | 1986 | 16 | 37.2   | −0.50                  | −0.84, −0.16 |
| Rizkalla et al. (Expt 2)\(^{(14)}\) | 1986 | 12 | 15.5   | −0.60                  | −1.31, 0.11 |
| Grigoresco et al.\(^{(10)}\) | 1988 | 8  | 9.6    | 0.50                   | −0.45, 1.45 |
| Blayo et al.\(^{(11)}\) | 1990 | 14 | 13.4   | −0.85                  | −1.63, −0.07 |
| Vaisman et al.\(^{(12)}\) | 2006 | 25 | 24.2   | −0.22                  | −0.73, 0.29 |
| Total                     |      | 75 | 100    | −0.40                  | −0.72, −0.08 |

Heterogeneity: \(\chi^2 = 0.03; \chi^2 = 77.90, df = 4 (P < 0.00001); I^2 = 95\%\)
Test for overall effect: \(Z = 2.67 (P = 0.008)\)

### Study Details

| Study or subgroup          | Year | n  | Wt (%) | MD, IV, random effects | 95% CI | Heterogeneity: \(\chi^2 = 0.03; \chi^2 = 77.90, df = 4 (P < 0.00001); I^2 = 95\%\) |
|---------------------------|------|----|--------|------------------------|--------|-----------------------------------------------------------------------------------|
| Rizkalla et al. (Expt 1)\(^{(14)}\) | 1986 | 16 | 26.9   | −0.11                  | −0.17, −0.06 |
| Rizkalla et al. (Expt 2)\(^{(14)}\) | 1986 | 12 | 25.1   | 0.06                   | −0.06, 0.17 |
| Grigoresco et al.\(^{(10)}\) | 1988 | 8  | 1.0    | −0.40                  | −2.26, 1.46 |
| Blayo et al.\(^{(11)}\) | 1990 | 14 | 19.9   | −0.77                  | −0.99, −0.55 |
| Sunhag et al.\(^{(13)}\) | 2002 | 24 | 27.2   | −0.30                  | −0.34, −0.26 |
| Total                     |      | 74 | 100    | −0.25                  | −0.44, −0.07 |

### Study Details

| Study or subgroup          | Year | n  | Wt (%) | MD, IV, random effects | 95% CI | Heterogeneity: \(\chi^2 = 1455.09; \chi^2 = 1180.33, df = 3 (P < 0.00001); \hat{R} = 100\%\) |
|---------------------------|------|----|--------|------------------------|--------|-----------------------------------------------------------------------------------|
| Rizkalla et al. (Expt 1)\(^{(14)}\) | 1986 | 16 | 29.3   | −57.82                 | −60.56, −55.07 |
| Rizkalla et al. (Expt 2)\(^{(14)}\) | 1986 | 12 | 29.3   | 7.64                   | 3.25, 12.03 |
| Grigoresco et al.\(^{(10)}\) | 1988 | 8  | 12.1   | −2.08                  | −91.53, 87.36 |
| Sunhag et al.\(^{(13)}\) | 2002 | 24 | 29.3   | 2.17                   | −0.34, 4.69 |
| Total                     |      | 60 | 100    | −14.33                 | −54.85, 26.18 |

### Forest Plots

Fig. 1. Forest plots of controlled feeding trials investigating the effect of isoenergetic exchange of ‘catalytic’ fructose doses (≤36 g/d) for other carbohydrates on glycaemic endpoints: (a) HbA1c, (b) fasting blood glucose (FBG) and (c) fasting blood insulin (FBI). Paired analyses were applied to the one cross-over trial by Grigoresco et al.\(^{(10)}\). To mitigate a unit-of-analysis error, we used only the starch comparison for Blayo et al.\(^{(11)}\) and the glucose comparison for Rizkalla et al. (Expt 1 and 2)\(^{(14)}\). Values are between-treatment end differences for five of the six trials (Grigoresco et al.\(^{(10)}\), Blayo et al.\(^{(11)}\), Vaisman et al.\(^{(12)}\), and Sunehag et al.\(^{(13)}\), Rizkalla et al. (Expt 1)\(^{(14)}\)) in the HbA1c analysis and for all trials in the FBG and FBI analyses, as change-from-baseline data were not available. \(P\) values are for generic inverse variance random-effects models, with differences expressed as mean differences (MD) with 95% CI\(^{(9)}\). Inter-study heterogeneity was tested by Cochrane’s \(Q\) statistic (\(\chi^2\)) at a significance level of \(P<0.10\) and quantified by \(I^2\)\(^{(9)}\). CHO, carbohydrate.
Methods

Study selection

We conducted separate searches of the effect of ‘catalytic’ doses of fructose on glycaemic endpoints (fasting blood glucose, fasting blood insulin and HbA1c), fasting TAG, body weight, blood pressure and uric acid in human subjects in MEDLINE, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials. We defined a ‘catalytic’ fructose intake in chronic feeding trials as 36 g/d based on doses of ≤10 g/bolus in acute trials\(^5\)\(^–\)\(^7\), allowing for three meals (10 g/meal) and two snacks (3 g/snack) per d. Trials that were <7 d follow-up, administered fructose intravenously, lacked an adequate control or did not provide suitable endpoint data were excluded. The study has been registered in the ClinicalTrials.gov registry (study identifier: NCT01363791).

Data extraction

At least two reviewers independently reviewed and extracted relevant data from each report on trial characteristics and outcomes. The quality of each study was assessed using the Heyland Methodological Quality Score (MQS)\(^8\). Disagreements were reconciled by consensus. Differences in mean values and standard deviations were extracted as the main endpoints. Trials that did not report either had these calculated from the available data. Missing standard deviation values were calculated from the available statistics or imputed using standard formulae\(^9\).

Statistical analyses

Data were analysed using Review Manager (RevMan) 5.1.4 (The Nordic Cochrane Centre, The Cochrane Collaboration). Meta-analyses were conducted using the generic inverse variance method using random-effects models with data expressed as mean differences (MD) with 95 % CI. Between-treatment change-from-baseline differences were preferred over end differences as the primary endpoint. We approximated paired analyses for the one cross-over trial\(^10\)\(^–\)\(^14\) using a conservative correlation coefficient (0.5) with sensitivity analyses at 0.25 and 0.75. To mitigate a unit-of-analysis error in the trials by Blayo et al.\(^{11}\) and Rizkalla et al. (Expt 1 and 2)\(^{14}\), we used only the starch and glucose comparisons, respectively. This approach of using a single arm as opposed to combing arms was selected, so as to minimise the influence of heterogeneity. Inter-study heterogeneity was tested by the \(Q\) statistic with the significance level set at \(P<0.10\) and quantified by the \(I^2\) statistic, where \(I^2 \approx 50\%\) is the evidence of substantial heterogeneity\(^9\). Sources of heterogeneity were investigated by subgroup analyses (diabetes status, comparator, fructose delta, fructose form, follow-up, MQS, randomisation and design). Publication bias was investigated by inspection of funnel plots.

Results

Search results

Fig. S1 of the supplementary material (available at http://www.journals.cambridge.org/bjn) shows the flow of the literature applying the systematic search and selection strategies. The search identified 7762 eligible reports. A total of five reports\(^{10\)–\(^14\) providing data for six trials were selected for analyses.

Trial characteristics

The trial characteristics are shown in Table 1. There were six trials in 118 subjects\(^{10\)–\(^14\)). All six (100 %) trials were randomised. Of these trials, one (17 %) used a cross-over design. Starch (four comparisons), glucose (two comparisons) and sucrose (one comparison) were the comparators. Fructose was administered in liquid or mixed formats at a median dose of 32.5 (range 22.5–36) g/d. Of the trials, three (50 %) used metabolically controlled designs. Background diets in the trials consisted of 25–60 % energy as carbohydrate, 25–50 % energy as fat and 15–25 % energy as protein. The median follow-up was 6 (range 1–52) weeks. The Heyland MQS in the trials ranged from 6 to 10 with four trials (67 %) considered high quality (MQS \(\geq 8\)).

Glycaemic effects of ‘catalytic’ fructose feeding

Fig. 1 shows the effect of ‘catalytic’ fructose doses on fasting glucose, fasting insulin and HbA1c. HbA1c was significantly reduced (MD \(-0.40, 95\%\) CI \(-0.72, -0.08\) without evidence of heterogeneity, while fasting glucose was significantly reduced (MD \(-0.25, 95\%\) CI \(-0.44, -0.07\) with significant inter-study heterogeneity \((I^2 = 95\%, P<0.001\)). There was no effect on fasting insulin, with the evidence of inter-study heterogeneity \((I^2 = 100\%, P<0.001)\) explained away by the removal of Rizkalla et al. (Expt 1)\(^{14}\) (data not shown). A \textit{priori} subgroup analyses (see Table S1 of the supplementary material, available at http://www.journals.cambridge.org/bjn) showed significant effect modification by diabetes status, comparator, follow-up, fructose form and MQS for fasting glucose; and comparator and fructose form for fasting insulin. None of the subgroup analyses explained away the heterogeneity for fasting glucose or insulin. The results of HbA1c and fasting glucose were sensitive to the removal of individual trials, and the results of HbA1c were sensitive to the correlation used (0.75) for paired analyses (data not shown).

Other metabolic effects of ‘catalytic’ fructose feeding

There was no effect of ‘catalytic’ fructose on body weight, TAG or uric acid without evidence of significant heterogeneity (see Fig. S2 of the supplementary material, available at http://www.journals.cambridge.org/bjn). None of the subgroup analyses was significant (see Table S2 of the supplementary material, available at http://www.journals.cambridge.org/bjn). Sensitivity analyses did not alter the results (data not shown).
Publication bias

Funnel plots for each of the analyses were inspected for the presence of publication bias (see Fig. S3 of the supplementary material, available at http://www.journals.cambridge.org/bjn). There was no evidence of funnel plot asymmetry, although the small number of trials made assessment difficult.

Discussion

This small meta-analysis of six controlled feeding trials in 118 subjects over a median follow-up of 6 weeks showed that ‘catalytic’ doses (22.5–36 g/d) of fructose in isocaloric exchange for other carbohydrates may improve glycaemic control without adversely affecting other cardiometabolic risk factors. The reduction in HbA1c of 0.4% was clinically significant, lying at the lower limit of efficacy expected for oral hypoglycaemic agents\(^{(2,15)}\). These results support an earlier meta-analysis by Livesey & Taylor\(^{(3,19)}\), which did not show a dose threshold for HbA1c reductions across a wider dose range of fructose.

A benefit of ‘catalytic’ doses of fructose has implications for the benefit of low-GI fruit. In a secondary analysis of a randomised controlled trial investigating the effect of a 6-month low-GI diet compared with a high-cereal fibre diet in 152 participants with type 2 diabetes\(^{(40)}\), we showed that low-GI fruit intake was the strongest independent predictor of HbA1c. The HbA1c decrease of 0.5% (highest v. lowest quartile of low-GI fruit intake) was similar to that seen in the present analysis, despite none of the trials in the meta-analysis using fruit. Although it is unclear whether this reduction in HbA1c was attributable to a ‘catalytic’ effect of fructose, its ability to lower the GI of the diet, or both, the low-GI fruit increase (2.2 servings/d) was equivalent to a ‘catalytic’ increase in fructose, which expressed as the most commonly consumed low-GI fruit in the study, apples, represents approximately 24 g/d of fructose.

A dose threshold for harm, however, remains an important consideration for fructose\(^{(41)}\). The ‘catalytic’ mechanism through which fructose is thought to operate, up-regulation of glucokinase, may under certain circumstances contribute to increased de novo lipogenesis with downstream metabolic sequelae\(^{(18)}\). Despite showing an improvement in HbA1c, the meta-analysis by Livesey & Taylor\(^{(19)}\) showed a consistent TAG raising effect of fructose at doses >100 g/d (>95th percentile total US fructose intake\(^{(20)}\)). In another meta-analysis of controlled feeding trials, we also showed that fructose in excess of the Canadian Diabetes Association threshold of >60 g/d\(^{(21)}\) increased TAG in type 2 diabetes\(^{(1)}\). Body-weight raising effects have otherwise been restricted to more extreme doses in hyperenergetic feeding trials (+18 to 50% energy)\(^{(17)}\), making it difficult to disentangle the relative contributions of excess fructose and energy. Sugar-sweetened beverage intakes as low as 1–2 servings/d, nevertheless, have been associated with overweight/obesity, the metabolic syndrome and diabetes in meta-analyses of prospective cohort studies\(^{(22)}\). The present findings confirm that fructose at intakes below these thresholds does not appear to have adverse effects on related cardiometabolic risk factors: fasting insulin, body weight, TAG or uric acid.

Limitations of the present analysis need to be considered. First, only 2–6 trials were included in the meta-analyses for each endpoint. It meant that effects were sensitive to the removal of individual trials, there may have been too little power to detect some differences and publication bias was difficult to assess reliably. Second, the trials were of short duration with only three of the six trials ≥8-weeks. It is possible that shorter trials may have underestimated the true effect on HbA1c, given the evidence of a \(t_{1/2}\) for HbA1c reductions of 35.2 d\(^{(22)}\). Subgroup analyses, however, did not show effect modification by follow-up. Third, inter-study heterogeneity complicated the analyses of fasting glucose and insulin. Although the removal of Rizkalla et al. (Expt 1)\(^{(44)}\) explained the heterogeneity for fasting insulin, sensitivity and subgroup analyses did not explain the heterogeneity for fasting glucose. Random-effects models, however, were used to address residual heterogeneity in all analyses. Finally, although there was a preference for change-from-baseline differences, end differences were used almost exclusively owing to the data reported. There was, however, no evidence of baseline differences between the trials (data not shown).

In conclusion, this small meta-analysis of controlled feeding trials supports earlier \(^{(15)}\) C NMR spectroscopy investigations\(^{(3,4)}\) and acute feeding studies\(^{(5–7)}\) showing that ‘catalytic’ doses (≤36 g/d) of fructose may improve glycaemic control. This benefit is seen without the adverse cardiometabolic effects reported when fructose is fed at high doses or as excess energy. The strength of these conclusions is limited by the small number of trials and their relatively short duration, especially in relation to HbA1c measurements. That such a small number of eligible trials were identified despite our broad inclusion criteria reinforces that there is a lack of adequate data. To clarify the effect of ‘catalytic’ doses of fructose and low-GI fruit as sources of ‘catalytic’ doses of fructose on glycaemic control, larger and longer-term (≥6 months) feeding trials are required.

Acknowledgements

This study was funded by a Canadian Institutes of Health Research (CIHR) Knowledge Synthesis grant and a grant from the Calorie Control Council. J. L. S. was supported by a Province of Ontario Postdoctoral Fellowship, the Edie Steinberg Scholarship Fund and the Edward Christie Stevens Fellowship in Medicine. A. M. was funded by a CIHR Master’s award. D. J. A. J. was funded by the Government of Canada through the Canada Research Chair Endowment. None of the sponsors had a role in any aspect of the present study, including design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. J. L. S. has received several unrestricted travel grants to present research at meetings from The Coca-Cola Company and is a co-investigator on an unrestricted research grant from The Coca-Cola Company. J. L. S. has also received travel funding and honoraria from the Archer Daniels Midland, International Life
Metabolic effects of ‘catalytic’ fructose 423

Sciences Institute (ILSI) North America and Abbott Nutrition Canada; and research support, consultant fees and travel funding from Pulse Canada. R. J. d. S, J. B. and C. W. C. K. are co-investigators on an unrestricted grant from The Coca-Cola Company. C. W. C. K. has served on the scientific advisory board, received research support, travel funding, consultant fees, or honoraria from Pulse Canada, Barilla, Solae, Unilever, Hain Celestial, Loblaws, Inc., Oldways Preservation Trust, the Almond Board of California, the International Nut Council, Paramount Farms, the California Strawberry Commission, the Canola and Flax Councils of Canada, and Saskatchewan Pulse Growers. C. W. C. K. also receives partial salary funding from research grants provided by Unilever, Loblaw’s and the Almond Board of California. D. J. A. J. holds an unrestricted grant from The Coca-Cola Company and has served on the scientific advisory board for or received research support, consultant fees or honoraria from Barilla, Solae, Unilever, Hain Celestial, Loblaws, Inc., Sanitarium Company, Herbalife International, Pacific Health Laboratories, Inc., Metagenics/MetaProteomics. Bayer Consumer Care, Oldways Preservation Trust, The Almond Board of California, The California Strawberry Commission, Orafti, the Canola and Flax Councils of Canada, Pulse Canada, the Saskatchewan Pulse Growers, and Abbott Nutrition Canada. D. J. A. J. also holds additional grant support from the CIHR, Canadian Foundation for Innovation (CFI), Ontario Research Fund (ORF), and Advanced Foods and Material Network (AFMNet). T. M. S. W. is the President, A. L. J. a Vice-President and Director of Research and L. C. a casual Clinical Research Coordinator at GI Laboratories, Toronto, Canada. A. I. C., A. M., A. J. C., V. H., D. W., M. E. Y., M. D. B. and L. A. L. have no declared conflicts of interest related to this paper.

References

1. Sievenpiper JI, Carleton AJ, Chatha S, et al. (2009) Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. Diabetes Care 32, 1930–1937.

2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2008) Canadian diabetes association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 32, S1–S201.

3. Hawkins M, Gabrieli I, Wozniak R, et al. (2002) Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes. Diabetes 51, 606–614.

4. Petersen KF, Laurent D, Yu C, et al. (2001) Stimulating effects of low-dose fructose on insulin-stimulated hepatic glycogen synthesis in humans. Diabetes 50, 1263–1268.

5. Moore MC, Cherrington AD, Mann SL, et al. (2000) Acute fructose administration decreases the glycemic response to an oral glucose tolerance test in normal adults. J Clin Endocrinol Metab 85, 4515–4519.

6. Moore MC, Davis SN, Mann SL, et al. (2001) Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes Care 24, 1882–1887.

7. Heacock PM, Hertzler SR & Wolf BW (2002) Fructose pre-feeding reduces the glycemic response to a high-glycemic index, starchy food in humans. J Nutr 132, 2601–2604.

8. Heyland DK, Novak F, Drover JW, et al. (2001) Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 286, 944–953.

9. JPT Higgins and S Green (editors) (2011) Cochrane Hand- book for Systematic Reviews of Interventions version 5.1.0 (updated march 2011). The Cochrane Collaboration. www.cochrane-handbook.org.

10. Grigorescu C, Rizkalla SW, Halton P, et al. (1998) Lack of detectable deleterious effects on metabolic control of daily fructose ingestion for 2 mo in NIDDM patients. Diabetes Care 21, 546–550.

11. Blayo A, Fontville AM, Rizkalla S, et al. (1990) Effets metabo- liques de la consommation quotidienne pednant un an de saccharose ou de fructose par des diabetiques (Metabolic effects of daily consumption a year SARP sucrose or fructose by diabetic). Med et Nut 26, 909–913.

12. Vaisman N, Niv E & Zdikavsky V (2006) Catalytic amounts of fructose may improve glucose tolerance in subjects with uncontrolled non-insulin-dependent diabetes. Clin Nutr 25, 617–621.

13. Sunehag AL, Toffolo G, Treuth MS, et al. (2002) Effects of dietary macronutrient content on glucose metabolism in children. J Clin Endocrinol Metab 87, 5168–5178.

14. Rizkalla SW, Baigts F, Fumeron F, et al. (1986) Comparative effects of several simple carbohydrates on erythrocyte insulin receptors in obese subjects. Pharmacol Biochem Behav 25, 681–688.

15. U.S.D.o.H.a.H.S., FDA, CDER (2008) Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Bio- logics for Treatment and Prevention (DRAFT GUIDANCE). Rockville, MD: U.S. Department of Health and Human Ser- vices, Food and Drug Administration, Center for Drug Evalua- tion and Research (CDER) pp. 1–30.

16. Jenkins DJ, Srirakul K, Kendall CW, et al. (2011) The relation of low glycaemic index fruit consumption to glycae- mic control and risk factors for coronary heart disease in type 2 diabetes. Diabetologіа 54, 271–279.

17. Sievenpiper JI, de Souza RJ, Kendall CW, et al. (2011) Is fruc- tose a story of mice but not men? J Am Diet Assoc 111, 219–220.

18. Peter A, Stefan N, Cegan A, et al. (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96, E1126–E1130.

19. Livesey G & Taylor R (2008) Fructose consumption and con- sequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of inter- vention studies. Am J Clin Nutr 88, 1419–1437.

20. Marriott BP, Cole N & Lee E (2009) National estimates of diet- ary fructose intake increased from 1977 to 2004 in the united states. J Nutr 139, 1228S–1235S.

21. Malik VS, Popkin BM, Bray GA, et al. (2010) Sugar-sweet- ened beverages, obesity, type 2 diabetes mellitus, and cardio-vascular disease risk. Circulation 121, 1356–1364.

22. Rech ME (1996) Observations on the decay of glycated hemoglobin HbA1c in diabetic patients. Exp Clin Endocrinol Diabetes 104, 102–105.